A5101771342- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Breast Cancer Treatment Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Effects of Radiation Exposure
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Radiation Therapy and Dosimetry
- Reproductive Biology and Fertility
- Reproductive System and Pregnancy
- Esophageal and GI Pathology
- Multiple Myeloma Research and Treatments
- Management of metastatic bone disease
- Gynecological conditions and treatments
- Endometrial and Cervical Cancer Treatments
- Cancer Treatment and Pharmacology
St James's University Hospital
2017-2025
Dehradun Institute of Technology University
2025
University of Pittsburgh Medical Center
2025
Leeds Teaching Hospitals NHS Trust
2015-2024
Graduate School USA
2023
Index Medical College, Hospital & Research Centre
2023
Clatterbridge Cancer Centre NHS Foundation Trust
2009-2016
Manchester Academic Health Science Centre
2014
University of Manchester
2008-2014
The Christie NHS Foundation Trust
2014
Abstract There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2 inhibition. In arm B2 of the National Lung Matrix Trial 54 patients NSCLC received vistusertib, which 49 were (30 KRAS mutation (B2D), 19 without (B2S)). Objective response (OR) durable clinical benefit (DCB) rates 95% credible...
BACKGROUND: Preclinical data have indicated the anti-epidermal growth factor receptor (EGFR) agent cetuximab (Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed clinical study. We report results of an original study initiated 2007, where was tested with radiotherapy (RT) alone locally advanced cancer phase II trial (PACER). METHODS: Patients (n = 21) received loading dose (400 mg/m2) and weekly (250 during RT (50.4 Gy 28 fractions). Toxicity...
Patient motion is an important factor affecting the quality of external beam radiotherapy in breast patients. We analyse a dense set surface points on patients throughout their treatment schedule to assess magnitude and stability motion, particular, with respect volume. use optical sensor measure 13 cancer Patients were divided into two cohorts dependent upon Measurements made during delivery for average 12 fractions per patient (total 158 datasets). The each point parameterized terms its...
Isotoxic dose escalation schedules such as IDEAL-CRT [isotoxic and acceleration in lung cancer chemoradiation therapy] (ISRCTN12155469) individualize doses prescribed to tumors, generating a fixed modeled risk of radiation pneumonitis. Because the beam penumbra is broadened lung, choice collimator margin an important element optimization isotoxic conformal therapy for cancer.
Purpose/objectives A recent study has shown that tight conformity of lung Stereotactic Ablative Radiotherapy (SABR) plans might worsen loco-regional control and can predict distant metastases. The aims to report overall survival (OS), progression-free (PFS), local recurrence free (LRFS), dosimetry early-stage cancer patients treated with SABR try explore any dosimetric predictor outcomes.Material methods Patients in our institute (May 2009–August 2018) were included. Electronic medical...
Stage III unresectable locally advanced non-small cell lung cancer (NSCLC) is a complex disease group with poor long-term survival. Clinical data suggests curative intent concurrent chemoradiotherapy (CCRT) superior to sequential (SCRT) approach but comes additional toxicities. We report real world regarding overall survival and toxicity aid clinical decision making in balancing optimal management treatment tolerability.Retrospective analysis of data, toxicities, rates completion were...
The objective of this study was to assess treatment outcomes in a large case series cervical cancer patients undergoing postoperative radiotherapy single center. Case notes women referred the Christie Hospital during 1985-1997 for adjuvant were reviewed. Of 478 eligible analysis, 282 (58.9%) underwent radical hysterectomy and 196 (41.1%) had nonradical hysterectomy. disease-specific 5-year survival population is 70.1%, with risk developing any recurrence 30.5% grade 3 morbidity rate 3.9%....